Categories
Uncategorized

Emapalumab

Emapalumab (sold under the brand name Gamifant) is a fully human monoclonal antibody medication that targets and neutralizes interferon gamma (IFNγ), a pro-inflammatory protein.

Approved for adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (pHLH) or macrophage activation syndrome (MAS) in Still’s disease.

Neutralizes free and receptor-bound IFNγ to block hyperinflammatory signaling cascades.

Dosage: Given as a 1 mg/kg intravenous (IV) infusion twice weekly alongside dexamethasone.

Side Effects: Carries risks of severe infections, hypertension, infusion reactions, and fever.

Live vaccines are contraindicated during and shortly after therapy.

 

Views: 1

Leave a Reply

Your email address will not be published. Required fields are marked *